Prognostic value of radiological extranodal extension (rENE) detected by computed tomography (CT) for predicting outcomes in locally advanced head and neck squamous cell cancer (LAHNSCC) patients treated with radical concurrent chemoradiotherapy (CCRT).
A retrospective analysis of patients administered neoadjuvant chemotherapy (NACT) with paclitaxel plus carboplatin with oral metronomic chemotherapy (OMCT) in locally advanced borderline resectable/technically unresectable head and neck cancers.
Efficacy and safety of neoadjuvant chemotherapy (NACT) with paclitaxel plus carboplatin and oral metronomic chemotherapy (OMCT) in patients with technically unresectable oral squamous cell carcinoma (OSCC).
Diclofenac versus tramadol for mucositis related pain in head and neck cancer patients undergoing concurrent chemoradiation – a phase 3 study
The efficacy of low-dose immunotherapy in head-and-neck cancer
Quality of life without toxicity or symptoms analysis of a randomized controlled clinical trial comparing efficacy of cabazitaxel versus docetaxel in recurrent head and neck cancer
Adding to the debate on once-a-week versus once-every-3-weeks cisplatin dosing in concurrent chemoradiotherapy for locally advanced head and neck squamous cell cancer
Quality of life and quality-adjusted time without toxicity in palliatively treated head-and-neck cancer patients
Distress Management in Patients With Head and Neck Cancer Before Start of Palliative Chemotherapy: A Practical Approach
Long-term survival outcomes of technically unresectable carcinoma maxilla postinduction chemotherapy
Influence of Hypothyroidism After Chemoradiation on Outcomes in Head and Neck Cancer
Toxicity and tolerance of concurrent docetaxel with radiotherapy in cisplatin ineligible head and neck cancer patients.
Results of a randomized phase III study of nimotuzumab in combination with concurrent radiotherapy and cisplatin versus radiotherapy and cisplatin alone, in locally advanced squamous cell carcinoma of the head and neck.
Quality of life in patients with locally advanced head and neck cancer treated with concurrent chemoradiation with cisplatin and nimotuzumab versus cisplatin alone - Additional data from a phase 3 trial.
865MO RMAC study: A randomized study evaluating the efficacy of metronomic adjuvant chemotherapy in patients with recurrent head and neck cancers post salvage surgery, not eligible for re-irradiation.
Outcome of neoadjuvant chemotherapy (NACT) with paclitaxel plus carboplatin and oral metronomic chemotherapy (OMCT) in patients with technically unresectable oral cavity squamous cell carcinoma (SCC).
Low-cost oral metronomic chemotherapy versus intravenous cisplatin in patients with recurrent, metastatic, inoperable head and neck carcinoma: an open-label, parallel-group, non-inferiority, randomised, phase 3 trial.
Articles Low-cost oral metronomic chemotherapy versus intravenous cisplatin in patients with recurrent, metastatic, inoperable head and neck carcinoma: an open-label, parallel- group, non-inferiority, randomised, phase 3 trial.
Results of a phase II randomized controlled clinical trial comparing efficacy of Cabazitaxel versus Docetaxel as second line or above therapy in recurrent head and neck cancer.
Evolving role of immunotherapy in head-and-neck cancers: A systemic review.
Once-a-Week Versus Once-Every-3-Weeks Cisplatin Chemoradiation for Locally Advanced Head and Neck Cancer: A Phase III Randomized Noninferiority Trial.
Current and Emerging Role of Chemotherapy in Oral Cancer.
Retrospective analysis of palliative metronomic chemotherapy in head and neck cancer.
343PQTWiST analysis to compare the benefit of Metronomic chemotherapy versus intravenous cisplatin for patients with Head and neck cancer.
337OQuality of life without toxicity or symptoms analysis of a randomized controlled clinical trial comparing efficacy of Cabazitaxel versus docetaxel in recurrent Head and Neck Cancer.
342PQOL analysis of a phase II randomized controlled clinical trial comparing efficacy of cabazitaxel versus docetaxel as second line or above therapy in recurrent head and neck cancer.
Results of a phase II randomized controlled clinical trial comparing eﬃcacyof Cabazitaxel versus Docetaxel as second line or above therapy in recurrent head and neck cancer.
1098PIncidence and impact of DPD mutation on neoadjuvant chemotherapy in head and neck cancers.
Phase III randomized trial comparing weekly versus three-weekly (W3W) cisplatin in patients receiving chemoradiation for locally advanced head and neck cancer.
Results of a phase II randomized controlled clinical trial comparing efficacy of cabazitaxel versus docetaxel as second-line or above therapy in recurrent head and neck cancer.
Incidence and impact of Dihydropyrimidine dehydrogenase gene mutation on neoadjuvant chemotherapy in head and neck cancers.
Carboplatin-based concurrent chemoradiation therapy in locally advanced head and neck cancer patients who are unfit for cisplatin therapy.
Neoadjuvant chemotherapy in geriatric head and neck cancers.
Role of neoadjuvant chemotherapy in advanced carcinoma of the hypopharynx and larynxLetter to the Editor.
A tertiary care experience with paclitaxel and cetuximab as palliative chemotherapy in platinum sensitive and nonsensitive in head and neck cancers.
Expectations and preferences for palliative chemotherapy in head and neck cancers patients.
386P Expectations and preferences for palliative chemotherapy in head and neck cancers patients.
Toxicity analysis of docetaxel, cisplatin, and 5-fluorouracil neoadjuvant chemotherapy in Indian patients with head and neck cancers.
Dihydropyrimidine dehydrogenase mutation in neoadjuvant chemotherapy in head and neck cancers: Myth or reality?.
Preoperative Chemotherapy and Metronomic Scheduling of Chemotherapy in Locally Advanced Oral Cancers.
Response to docetaxel and cisplatin induction chemotherapy of locally advanced head and neck squamous cell carcinoma: a multicenter, non-comparative, open-label interventional pilot study.
Toxicity, tolerance and outcomes of carboplatin based CTRT ( concurrent chemoradiation) in head and neck cancers in patients who were not fit for cisplatin based CTRT.
Time-Dependent Area under the ROC Curve for Optimum Biological Dose Detection.
An audit of the results of a triplet metronomic chemotherapy regimen incorporating a tyrosine kinase inhibitor in recurrent/metastatic head and neck cancers patients.
Health-related quality of life in patients with metastatic, relapsed, or inoperable squamous cell carcinoma of the head and neck in India.
Outcome of operable oral cavity cancer and impact of maintenance metronomic chemotherapy: A retrospective study from rural India.
Metronomic palliative chemotherapy in maxillary sinus tumor.
Efficacy of second‑line erlotinib in patients postprogression of first‑line chemotherapy in head and neck cancers.
Technically unresectable recurrent oral cancers: Is NACT the answer?.
Head and neck cancer in geriatric patients: Analysis of the pattern of care given at a tertiary cancer care center.
Cisplatin based adjuvant chemoradiation following neoadjuvant chemotherapy and surgery in advanced oral cavity cancers: A deliverable regimen?.
Molecular biology of head and neck cancers.
Chemoprevention in head and neck cancer.
Extra-lymphatic filariasis at reconstructive surgery flap site recurrence of head and neck cancer.
Neoadjuvant chemotherapy and surgical margin in technically unresectable buccal mucosa cancers.
Compliance With Neoadjuvant Chemotherapy in T4 Oral Cancers: Place, Person, Socioeconomic Status, or Assistance.
Neoadjuvant chemotherapy in advanced sinonasal teratocarcinosarcoma with intracranial extension: Report of two cases with literature review.
Does the use of induction chemotherapy in oral cavity cancer compromise subsequent loco-regional treatment delivery: Results from a matched pair analysis.
Neoadjuvant Chemotherapy in Technically Unresectable Oral Cancers: Does Human Papillomavirus Make a Difference?.
Neoadjuvant chemotherapy in technically unresectable carcinoma of external auditory canal.
Metronomic chemotherapy in platinum-insensitive failures and/or early failures postmultimodality management in oral cancers.
NACT in locally advanced oral cancers : Does HPV make a difference?.
Compliance to NACT in T4 oral cancers :The place, person, socioeconomic status or assistance.
Effect of early integration of specialized palliative care into standard oncologic treatment on the quality of life of patients with advanced head and neck cancers: A phase III randomized controlled trial.
Efficacy and safety of neoadjuvant chemotherapy (NACT) with paclitaxel plus carboplatin and oral metronomic chemotherapy (OMCT) in patients with technically unresectable oral cavity squamous cell carcinoma (SCC).
Excellent response to oral Metronomic chemotherapy in unresectable adenocarcinoma of external auditory canal.
Does DeCIDE Give a Decisive Answer Against Induction Chemotherapy in Head and Neck Cancers?.
Locoregional recurrences after postoperative Volumetric Modulated Arc Radiotherapy (VMAT) in oral cavity cancers in a resource constrained setting : experience and lessons learned.
A prospective randomized phase II study comparing metronomic chemotherapy with chemotherapy (single agent cisplatin), in patients with metastatic, relapsed or inoperable squamous cell carcinoma of head and neck.
Is taxane/platinum/5 fluorouracil superior to taxane/platinum alone and does docetaxel trump paclitaxel in induction therapy for locally advanced oral cavity cancers?.
Neoadjuvant chemotherapy followed by surgery in very locally advanced technically unresectable oral cavity cancers.
How safe is adjuvant RapidArc in Oral Cavity Cancers: An analysis of Marginal and Outfield Failures.
Recurrent sinonasal teratocarcinosarcoma with intracranial extension: Case report.
Weekly chemotherapy as Induction chemotherapy in locally advanced head and neck cancer for patients ineligible for 3 weekly maximum tolerable dose chemotherapy.
Tolerance and toxicity of neoadjuvant docetaxel, cisplatin and 5 fluorouracil regimen in technically unresectable oral cancer in resource limited rural based tertiary cancer center.
A phase II study comparing metronomic chemotherapy with chemotherapy (single-agent cisplatin), in patients with metastatic, relapsed, or inoperable squamous cell carcinoma of head and neck.
Neoadjuvant chemotherapy in very locally advanced technically unresectable oral cavity cancers.
Induction Chemotherapy in Technically Unresectable Locally Advanced Carcinoma of Maxillary Sinus.
PCN157. Health Related Quality of Life in Patients with Metastatic, Relapsed, or Inoperable Squamous Cell Carcinoma of the Head and Neck in India.
Guidelines for treatment of recurrent or metastatic head and neck cancer.
Referral pattern for neoadjuvant chemotherapy in the head and neck cancers in a tertiary care center.
Is there a role of induction chemotherapy followed by resection in T4b oral cavity cancers?.
Comparison of concomitant boost radiotherapy against concurrent chemoradiation in locally advanced oropharyngeal cancers: A phase III randomised trial.
Induction chemotherapy in technically unresectable locally advanced oral cavity cancers: Does it make a difference?.
Neo-adjuvant chemotherapy in advanced hypopharyngeal carcinoma.
Epidemiology of oral cancers referred for NACT, the demographics, clinical profile, and organ functions.
Are three drugs better than two and does docetaxel trump paclitaxel in induction therapy for locally advanced oral cavity cancers?.
Acute toxicity of neoadjuvant chemotherapy in oral cavity cancers: Can it be predicted?.
OP048: Induction chemotherapy in unresectable oral cavity cancers.
Oral Metronomic Chemotherapy in Recurrent, Metastatic and Locally Advanced Head and Neck Cancers.
Is There a Limitation of RECIST Criteria in Prediction of Pathological Response, in Head and Neck Cancers, to Postinduction Chemotherapy?.
Development of hyponatremia on neoadjuvant chemotherapy in locally advanced head & neck cancers.
Neoadjuvant chemotherapy followed by definitive local treatment in locally advanced carcinoma maxillary sinus.
Palliative chemotherapy in head and neck cancers: A tertiary care center experience with weekly paclitaxel and cetuximab.
Metronomic chemotherapy in advanced oral cancers.
Conformal Radiotherapy in the Treatment of Advanced Juvenile Nasopharyngeal Angiofibroma With Intracranial Extension: An Institutional Experience.
Acute Toxicities Experienced during Simultaneous Integrated Boost Intensity-modulated Radiotherapy in Head and Neck Cancers - Experience from a North Indian Regional Cancer Centre.
Preliminary results of SIB-IMRT in head and neck cancers: Report from a regional cancer center in northern India.
MMAP-08 CHEMO-REIRRADIATION (NORMOFRACTIONATED VS. HYPOFRACTIONATED) WITH OR WITHOUT BEVACIZUMAB IN RECURRENT ADULT DIFFUSE HIGH-GRADE GLIOMA (COBRA): PHASE III RANDOMIZED CONTROLLED TRIAL WITH A 2 X 2 FACTORIAL DESIGN.
Optimizing Postoperative Adjuvant Therapy in Elderly Patients with Newly Diagnosed Glioblastoma: Single-Institution Audit of Clinical Outcomes from a Tertiary-Care Comprehensive Cancer Center in India.
Expectation and Preferences with Palliative Systemic Therapy in Recurrent Gliomas
The story of two eyes- What to look for in the patient's eyes?
A cross-sectional audit of distress in patients undergoing adjuvant therapy or follow-up in central nervous system malignancies
RTHP-01. DOES THE EFFICACY OF SALVAGE RE-IRRADIATION IN RECURRENT MEDULLOBLASTOMA DEPEND UPON RISK-STRATIFICATION, SITE OF RELAPSE, AND MOLECULAR SUBGROUP?
Cross-Sectional Study of Temozolomide-Induced Chemotherapy-Induced Nausea and Vomiting in Patients with Glioma
RONC-17. DOES THE EFFICACY OF SALVAGE RE-IRRADIATION IN RECURRENT MEDULLOBLASTOMA DEPEND UPON RISK-STRATIFICATION, SITE OF RELAPSE, AND MOLECULAR SUBGROUP?
RONC-07. THE TALE OF 100 DIPGs AND RADIOTHERAPY
Shadow study: randomized comparison of clinic with video follow-up in glioma undergoing adjuvant temozolomide therapy
Prospective Longitudinal Assessment of Quality of Life and Activities of Daily Living as Patient-Reported Outcome Measures in Recurrent/ Progressive Glioma Treated with High-dose Salvage Re-irradiation.
P09.03 Bevacizumab in glioma: An experience from Tata Memorial Hospital
Rechallenge temozolomide in glioma: A case series from India
A case series of salvage CCNU in high-grade glioma who have previously received temozolomide from a tertiary care institute in Mumbai
Neoadjuvant Chemotherapy in Locally Advanced and Borderline Resectable Nonsquamous Sinonasal Tumors (Esthesioneuroblastoma and Sinonasal Tumor with Neuroendocrine Differentiation)
Shielding in whole brain irradiation in the multileaf collimator era: Dosimetric evaluation of coverage using SFOP guidelines against in-house guidelines
Standard maintenance therapy versus local consolidative radiation therapy and standard maintenance therapy in 1-5 sites of oligometastatic non-small cell lung cancer: A study protocol of phase III randomised controlled trial
Protocol for a phase II randomised controlled trial of TKI alone versus TKI and local consolidative radiation therapy in patients with oncogene driver-mutated oligometastatic non-small cell lung cancer
A randomized clinical trial evaluating the efficacy and safety of the addition of oral metronomic chemotherapy after completion of standard chemoradiation versus observation in patients with locally advanced esophageal and gastroesophageal junction squamous cell carcinoma.
The role of chemotherapy in patients with small cell lung cancer and poor performance status View supplementary material The role of chemotherapy in patients with small cell lung cancer and poor performance status
The efficacy and safety of first-line therapy for the epidermal growth factor receptor mutant non-small cell lung cancer in older versus younger patients: A pooled analysis of two randomized controlled trials
Development and validation of a predictive score, for identifying poor eastern cooperative oncology group performance status (performance status 3–4) advanced nonsmall cell lung cancer patients who are likely to benefit from tyrosine kinase inhibitors
1294PReal world data of practice patterns and outcomes for pemetrexed plus platinum as neoadjuvant chemotherapy in adenocarcinomas of lung from a tertiary cancer center of India: Looking beyond the usual paradigm
Quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis of a Phase III randomized trial to compare the benefit of gefitinib versus pemetrexed/ carboplatin for epidermal growth factor receptor-mutated non-small cell lung cancer
Strategic approaches to overcome resistance against Gram negative pathogens using β-lactamase inhibitors and β-lactam enhancers: The activity of three novel diazabicyclooctanes, WCK 5153, zidebactam (WCK 5107), and WCK 4234
Phase III open label randomized controlled trial comparing intravenous iron sucrose to oral ferrous sulphate (without erythropoiesis stimulating agents) in the treatment of cancer related iron deficiency anemia.
© 2022 All Rights Reserved by Prof. Vijay M. Patil.